drugset / Trial / NCT04524195
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1
Terminated
4 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CellSight Technologies, Inc. · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if the radioactive compound called \[18F\]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).
Timeline
- Start
- 2021-02-01
- Primary completion
- 2023-11-27
- Completion
- 2023-11-27
Outcome
Outcome not reported
Stopped: “The study is terminated because the PI left the institution.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-ARAG | Diagnostic / imaging agent | 185 mbq | Intravenous |